ClinicalTrials.Veeva

Menu

Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea

Allergan logo

Allergan

Status

Completed

Conditions

Glabellar Lines
Hyperhidrosis
Muscle Spasticity

Treatments

Biological: botulinum toxin Type A

Study type

Observational

Funder types

Industry

Identifiers

NCT02043145
EPI-MULT-100

Details and patient eligibility

About

This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines in clinical practice.

Enrollment

727 patients

Sex

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines.

Exclusion criteria

  • None.

Trial design

727 participants in 3 patient groups

Axillary Hyperhidrosis
Description:
Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
Treatment:
Biological: botulinum toxin Type A
Focal Spasticity
Description:
Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
Treatment:
Biological: botulinum toxin Type A
Glabellar Lines
Description:
Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
Treatment:
Biological: botulinum toxin Type A

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems